In premenopausal women, 5-year aromatase inhibitor therapy reduced the 25-year cumulative risk of contralateral breast cancer by an additional 1–2% compared to 5-year tamoxifen therapy. This evidence concerns the gene CYP19A1 and breast carcinoma.